Loading…
Gland Pharma (GLAND)₹3,302+5.41%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Gland Pharma reported sales of ₹1,804 Cr, up 19.7% from Jun 2025, and net profit of ₹317 Cr, up 47.5% year on year. For the year to Mar 2026, sales were ₹6,440 Cr and net profit ₹1,026 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,376 | 1,547 | 1,539 | 1,404 | 1,409 | 1,387 | 1,428 | 1,507 | 1,489 | 1,697 | 1,746 | 1,804 |
| Expenses | 1,051 | 1,192 | 1,182 | 1,140 | 1,112 | 1,027 | 1,080 | 1,140 | 1,175 | 1,263 | 1,232 | 1,313 |
| Operating Profit | 323 | 355 | 358 | 263 | 296 | 359 | 347 | 367 | 313 | 434 | 512 | 488 |
| OPM % | 24.0% | 23.1% | 23.0% | 19.0% | 21.1% | 26.0% | 24.1% | 24.1% | 21.0% | 26.1% | 29.0% | 27.0% |
| Other Income | 52.97 | 36.96 | 41.95 | 50.99 | 59.98 | 58.01 | 43.94 | 57.96 | 84.01 | 38.96 | 111 | 60.93 |
| Interest | 5.99 | 4.99 | 9.99 | 5.99 | 5.99 | 22.97 | 6.99 | 11.99 | 7.99 | 3.99 | 9.99 | 3.99 |
| Depreciation | 81.12 | 105 | 93.08 | 92.16 | 94.17 | 96.06 | 96.05 | 101 | 106 | 108 | 109 | 111 |
| Profit before tax | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax % | 32.9% | 32.0% | 35.0% | 33.9% | 35.9% | 31.9% | 34.9% | 31.0% | 34.9% | 27.9% | 27.9% | 26.9% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −16.93 | 0.00 | 0.00 |
| Net Profit | 193 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 366 | 317 |
| EPS (Rs) | 11.76 | 11.63 | 11.66 | 8.71 | 9.90 | 12.39 | 11.28 | 13.05 | 11.12 | 15.82 | 22.20 | 19.15 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,636 | 3,467 | 4,412 | 3,631 | 5,672 | 5,628 | 6,440 | 6,735 |
| Expenses | 1,682 | 2,165 | 2,896 | 2,607 | 4,342 | 4,359 | 4,808 | 4,983 |
| Operating Profit | 952 | 1,299 | 1,506 | 1,022 | 1,329 | 1,266 | 1,626 | 1,746 |
| OPM % | 36.0% | 38.1% | 34.0% | 28.0% | 24.0% | 23.1% | 25.0% | 25.9% |
| Other Income | 139 | 135 | 224 | 184 | 170 | 214 | 292 | 295 |
| Interest | 6.99 | 2.99 | 4.99 | 6.99 | 25.98 | 41.99 | 32.98 | 25.96 |
| Depreciation | 95.10 | 99.12 | 110 | 147 | 345 | 378 | 424 | 435 |
| Profit before tax | 994 | 1,336 | 1,620 | 1,056 | 1,133 | 1,064 | 1,466 | 1,588 |
| Tax % | 21.9% | 25.0% | 24.9% | 25.9% | 32.0% | 33.9% | 29.9% | — |
| Exceptional items | 12.95 | 0.00 | 2.99 | −39.84 | 0.00 | 1.99 | −14.94 | −16.93 |
| Net Profit | 771 | 995 | 1,210 | 780 | 771 | 698 | 1,026 | 1,127 |
| EPS (Rs) | 49.76 | 60.77 | 73.60 | 47.32 | 46.81 | 42.27 | 62.19 | 68.29 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 42.9% | 41.9% | 32.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 16.02 | 16.02 | 16.01 | 16.01 | 16.02 | 16.02 | 16.03 |
| Reserves | 3,622 | 5,867 | 7,120 | 7,915 | 8,693 | 9,114 | 10,328 |
| Borrowings | 5.01 | 5.01 | 5.01 | 4.01 | 373 | 314 | 285 |
| Other Liabilities | 437 | 591 | 673 | 818 | 1,522 | 1,716 | 1,816 |
| Total Liabilities | 4,079 | 6,479 | 7,815 | 8,755 | 10,605 | 11,161 | 12,445 |
| Fixed Assets | 971 | 957 | 1,508 | 1,578 | 3,963 | 4,166 | 4,512 |
| CWIP | 188 | 338 | 191 | 177 | 238 | 151 | 342 |
| Investments | 0.00 | 0.00 | 155 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 2,919 | 5,184 | 5,961 | 7,000 | 6,405 | 6,844 | 7,590 |
| Inventories | 758 | 1,279 | 1,191 | 1,953 | 1,662 | 1,690 | 1,751 |
| Trade receivables | 599 | 669 | 1,194 | 868 | 1,553 | 1,512 | 1,885 |
| Cash & equivalents | 1,321 | 2,993 | 3,085 | 3,757 | 1,832 | 2,549 | 3,346 |
| Total Assets | 4,079 | 6,479 | 7,815 | 8,755 | 10,605 | 11,161 | 12,445 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 702 | 606 | 792 | 365 | 998 | 916 | 1,033 |
| Cash from investing activity | −763 | −1,521 | −1,001 | 1,212 | −1,753 | 1,720 | 188 |
| Cash from financing activity | −7.03 | 1,243 | 35.15 | 15.06 | −802 | −434 | −418 |
| Net cash flow | −67.25 | 324 | −175 | 1,595 | −1,559 | 2,207 | 807 |
| Capex | 195 | 229 | 521 | 223 | 397 | 393 | 492 |
| Free cash flow | 531 | 378 | 269 | 141 | 600 | 522 | 539 |
| CFO / OP % | 99.0% | 70.0% | 78.9% | 65.9% | 97.9% | 99.9% | 90.9% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 83 | 71 | 99 | 88 | 100 | 99 | 107 |
| Inventory days | 250 | 312 | 205 | 421 | 278 | 294 | 284 |
| Days payable | 82 | 97 | 80 | 127 | 129 | 143 | 136 |
| Cash conversion cycle | 251 | 286 | 225 | 382 | 250 | 250 | 255 |
| Working capital days | 161 | 169 | 168 | 242 | 155 | 173 | 145 |
| ROCE % | — | 28.0% | 25.0% | 15.0% | 14.0% | 12.0% | 15.0% |
For the Jun 2026 quarter, Gland Pharma reported sales of ₹1,804 Cr, up 19.7% year on year and net profit of ₹317 Cr, up 47.5% year on year. The operating margin was 27.0%.
Gland Pharma's sales for the year to Mar 2026 were ₹6,440 Cr; over the last twelve months they were ₹6,735 Cr.
Net profit for the year to Mar 2026 was ₹1,026 Cr, and ₹1,127 Cr over the last twelve months. Earnings per share over the same trailing period were ₹68.29.
Gland Pharma reported borrowings of ₹285 Cr at Mar 2026, against cash and equivalents of ₹3,346 Cr.
Cash from operations was ₹1,033 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹539 Cr.